Last updated on October 7, 2026 · Originally published December 11, 2022
Scientifically reviewed by Chana Frenkel, Ph.D.
A decade of psilocybin depression research has produced something rarer than hype: a real evidence base, with real results in both directions. Randomized trials have repeatedly found that one or two supervised doses of psilocybin, given with structured psychological support, can reduce depression symptoms quickly – sometimes within a day – with effects that often persist for weeks. According to company-announced topline results, two phase 3 trials have now met their primary endpoints, and a US regulatory filing is expected. But the same literature includes a rigorous trial that missed its primary endpoint, a head-to-head comparison that failed to beat a standard antidepressant, and an unresolved methodological problem – participants can usually tell whether they received psilocybin or a placebo, so the trials are rarely truly blind – that complicates every effect size in the field. Here is what the trials actually show.
How did modern psilocybin depression research begin?
One landmark of the modern clinical era – which grew alongside earlier pilot work and a parallel depression program at Imperial College London – came from Johns Hopkins, where Roland Griffiths and colleagues ran a randomized, double-blind trial of high-dose versus placebo-like low-dose psilocybin in patients with life-threatening cancer and clinically significant depression or anxiety. Published in 2016, it reported substantial decreases in depression and anxiety that were sustained at six months, with the mystical-type quality of the session experience being associated with response. [1] The study was small and its participants faced a specific clinical situation, but it established the template nearly every later trial has used: careful screening, one or two supervised dosing sessions, and preparation and integration meetings around them.
(How cannabis science opened the door to this research in the first place is a story of its own — see how cannabis led us to psilocybin research.)
What happened when psilocybin faced an antidepressant head-to-head?
The field’s first reality check came in 2021, when Robin Carhart-Harris and colleagues at Imperial College London compared two psilocybin sessions against six weeks of daily escitalopram – a standard SSRI – in a randomized, double-blind trial. On the prespecified primary measure, psilocybin did not significantly outperform escitalopram: the two-point difference between groups did not reach statistical significance (P = 0.17). The trial therefore established neither superiority nor equivalence – its primary result was inconclusive. Secondary outcomes generally favored psilocybin but were not corrected for multiple comparisons. [2] The distinction matters, because “did not beat an SSRI in this trial” is a very different sentence from either “worked just as well” or “outperformed everything we have” – and only the first is what the data show.
What did the dose-ranging and single-dose trials show?
The largest phase 2 trial, run by COMPASS Pathways across 22 sites, randomized 233 people with treatment-resistant depression to a single 25 mg, 10 mg, or 1 mg dose of COMP360, COMPASS’s p. At week 3, the 25 mg group’s depression scores (on the MADRS scale) had fallen 6.6 points more than the 1 mg control group’s – a statistically significant difference. [4] Durability was the weak point: by week 12, sustained response was 20.3% in the 25 mg group versus 10.1% in the control – double, but a minority. Adverse events rose with dose (84% of the 25 mg group reported at least one), and the investigators reported that suicidal ideation or self-injurious behavior occurred in all groups, in proportions numerically higher in the 25 mg and 10 mg groups than in the 1 mg group. [4]
Two independent single-dose trials strengthened the efficacy signal. In Zurich, a placebo-controlled trial in 52 adults with major depression found that a single moderate dose (0.215 mg/kg) reduced MADRS scores by 13 points more than placebo at 14 days (P = 0.0011). [5] In a US multi-site trial published in JAMA in 2023, a single 25 mg dose outperformed an active niacin placebo by 12.3 MADRS points at day 43 in 104 adults with major depression; there were no serious treatment-emergent adverse events, though overall and severe adverse events were more common with psilocybin. [6]
The newest placebo-controlled study – the UK’s first publicly funded psilocybin trial, published in Nature Medicine in 2026 – was a phase 2 feasibility trial at a single NHS site: its primary purpose was to determine whether a larger public-healthcare trial is practical, though its secondary efficacy findings were striking. Sixty adults with treatment-resistant depression received a single 25 mg dose or placebo, with psychological support. The psilocybin group’s MADRS scores were 10.4 points lower at week 3 (Cohen’s d = −1.70), and the difference was sustained at week 6, with no serious adverse events reported. [7] That is a very large effect – but it was a secondary outcome in a feasibility-scale study, not a confirmatory primary result, and the authors’ own conclusion was appropriately modest: the findings support a future, larger efficacy trial.
What about the trial that missed its primary endpoint?
Any honest account has to sit with the EPIsoDE trial, published in JAMA Psychiatry in March 2026 – a German two-center, phase 2b study that was among the methodologically strictest yet run. It randomized 144 adults with treatment-resistant depression to different two-session dose sequences involving 25 mg psilocybin, 5 mg psilocybin, and an active nicotinamide placebo, given six weeks apart and embedded in a structured psychotherapy program. The primary endpoint – at least a 50% symptom reduction at week 6 – was measured immediately before the second session, while the comparison still reflected the first assigned dose. On that endpoint the trial failed: response rates were 17.0% with 25 mg versus 10.6% with placebo, a nonsignificant difference (adjusted odds ratio 1.73; 95% CI, 0.53–6.23; P = .19). [8] Secondary analyses of symptom-score changes provided exploratory evidence of a clinically meaningful effect. After the second session, symptoms remained lower on average, but all participants had then received 25 mg at least once and the original group differences disappeared, so the study could not establish an added benefit from a second dose. [8] Safety was mostly unremarkable, with two exceptions worth naming plainly: suicidal ideation on dosing days was more common with 25 mg (about 4%, versus 1–2% in the comparison groups), and there were two serious adverse reactions after 25 mg, including one case of hallucinogen persisting perception disorder. [8]
The same group’s naturalistic follow-up, published in mid-2026, tracked 126 of the 144 participants for a year. Symptom reductions persisted on average (about 7.7–7.9 points below baseline at both 6 and 12 months), with no significant differences between the original dose groups – but participants were free to resume antidepressants and other treatments, and many did, which makes the long-term data genuinely hard to attribute. [9]
Where do the phase 3 trials stand?
COMPASS Pathways has announced – as company-reported topline results, not yet confirmed in peer-reviewed publications – that both of its phase 3 trials in treatment-resistant depression met their primary endpoints, the first phase 3 evidence in the field. In COMP005 (258 participants, single 25 mg dose versus placebo), psilocybin beat placebo by 3.6 MADRS points at week 6; in COMP006 (581 participants, two doses of 25, 10, or 1 mg, given without background antidepressants though still with supervised psychological support), the 25 mg arm beat the 1 mg arm by 3.8 points at week 6, with effects reported from the day after dosing and an independent safety board finding no meaningful imbalance in suicidality between arms. [10] The other caution belongs next to the numbers themselves: the phase 3 effect sizes (3.6–3.8 points against control) are notably smaller than the differences reported in the smaller academic trials above – a common pattern as treatments move into larger, multicenter trials. The company has said it expects to complete a US regulatory submission in late 2026. [10]
Is it the drug, the therapy, or the expectation?
Three threads run through all of these results. First, no major trial has tested psilocybin bare: every one delivered it inside a structured protocol of preparation, supervised dosing, and integration. Our review of the literature found no completed randomized trial of psilocybin for depression without structured psychological support – so the evidence supports psilocybin-with-support, not psilocybin as a stand-alone pill. Second, durability is the field’s soft spot: the strongest controlled effects are measured at three to six weeks, a Johns Hopkins follow-up reported benefits lasting a year in a small cohort, [3] and the larger 12-month datasets are naturalistic and confounded by resumed treatments. [9]
Third, and most fundamental: blinding barely works. A person who receives 25 mg of psilocybin almost always knows it, and so do the placebo recipients – which means expectancy can inflate apparent benefit. A 2026 JAMA Psychiatry meta-analysis approached the problem indirectly, comparing psychedelic trials with open-label antidepressant trials – conditions under which participants in both generally knew what they were receiving. It found no significant efficacy difference between them, and concluded that the highly optimistic reading of psychedelic trials may partly reflect differences in blinding. [11] The FDA raised the same concerns in its 2023 draft guidance for psychedelic trials, and retained its trial-design and masking concerns in the final guidance issued in July 2026. [12] None of this means the drug does nothing – the dose-response findings and active-comparator designs argue otherwise – but it means every effect size in this field carries an unusually large asterisk, although conventional antidepressant trials are not immune to expectancy or functional unblinding either.
The same problem decided the fate of MDMA: two positive phase 3 trials, then a rejection — see what MDMA research shows for PTSD.
Where is any of this legal right now?
Psilocybin remains a Schedule I substance under US federal law, and no psilocybin product is FDA-approved for depression. Australia became the first country to allow authorized psychiatrists to prescribe it for treatment-resistant depression, as we reported when the change was announced. Oregon and Colorado run state-regulated psilocybin service programs that operate outside the medical system, and US regulators have repeatedly raised research production quotas as trial demand has grown. Ketamine, the other fast-acting option reshaping depression treatment, raises a parallel set of questions about durability and blinding — see our conversation with mood-disorders researcher Dr. Roger McIntyre for where that evidence stands. For a view from inside the industry hoping to sell psilocybin products, see our 2022 conversation with Derek Chase.
Research access is widening in other directions too – including trials of psilocybin’s effects on the aging brain. And the compound’s reach may extend beyond psychiatry altogether: a mouse study in Science found that two doses given before chemotherapy prevented nerve damage, with a human trial about to begin.For a person with depression in most of the world, however, lawful clinical access remains limited to trials or tightly controlled special-access programs.
The bottom line
Psilocybin with structured support is one of the most promising experimental treatments for depression in a generation – and it is still experimental. The consistent finding across a decade of trials is a rapid, meaningful reduction in depressive symptoms after one or two supervised doses, now supported by two phase 3 primary endpoints. The equally consistent caveats: one strict trial missed its primary endpoint, the head-to-head against an SSRI was inconclusive on its primary measure, effects fade for many people within months, numerical suicidality imbalances or safety signals have appeared at the highest dose in two trials, and expectancy complicates every effect estimate. What the research shows, in one sentence: psilocybin-assisted treatment works better than placebo in most – not all – controlled tests, for a period measured in weeks, in screened and supported patients – with the respective contributions of the drug, the psychological support, and expectancy still difficult to separate.
References
[1] Griffiths RR, Johnson MW, Carducci MA, Umbricht A, Richards WA, Richards BD, et al. Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial. J Psychopharmacol. 2016. doi:10.1177/0269881116675513
[2] Carhart-Harris R, Giribaldi B, Watts R, Baker-Jones M, Murphy-Beiner A, Murphy R, et al. Trial of psilocybin versus escitalopram for depression. N Engl J Med. 2021;384:1402-1411. doi:10.1056/NEJMoa2032994
[3] Gukasyan N, Davis AK, Barrett FS, Cosimano MP, Sepeda ND, Johnson MW, et al. Efficacy and safety of psilocybin-assisted treatment for major depressive disorder: Prospective 12-month follow-up. J Psychopharmacol. 2022. doi:10.1177/02698811211073759
[4] Goodwin GM, Aaronson ST, Alvarez O, Arden PC, Baker A, Bennett JC, et al. Single-dose psilocybin for a treatment-resistant episode of major depression. N Engl J Med. 2022;387:1637-1648. doi:10.1056/NEJMoa2206443
[5] von Rotz R, Schindowski EM, Jungwirth J, Schuldt A, Rieser NM, Zahoranszky K, et al. Single-dose psilocybin-assisted therapy in major depressive disorder: A placebo-controlled, double-blind, randomised clinical trial. eClinicalMedicine. 2023;56:101809. doi:10.1016/j.eclinm.2022.101809
[6] Raison CL, Sanacora G, Woolley J, Heinzerling K, Dunlop BW, Brown RT, et al. Single-dose psilocybin treatment for major depressive disorder: A randomized clinical trial. JAMA. 2023;330:843-853. doi:10.1001/jama.2023.14530
[7] Rucker JJ, Mantingh T, Kerr-Gaffney J, Bird C, Chu P, Modlin NL, et al. Psilocybin-assisted therapy for treatment-resistant major depressive disorder in a public healthcare setting: a randomized controlled trial. Nat Med. 2026. doi:10.1038/s41591-026-04541-0
[8] Mertens LJ, et al. Efficacy and safety of psilocybin in treatment-resistant major depression: The EPISODE randomized clinical trial. JAMA Psychiatry. 2026. doi:10.1001/jamapsychiatry.2026.0132
[9] Mertens LJ, Betzler F, Brand M, Evens R, Jungaberle A, Jungaberle H, et al. Long-term efficacy of psilocybin with adjunct psychotherapy in treatment-resistant major depression: 6- and 12-month naturalistic follow-up of a phase 2b trial. Psychother Psychosom. 2026. doi:10.1159/000552272
[10] Compass Pathways. Announcements of topline phase 3 results: COMP005 (June 23, 2025) and COMP006 (February 17, 2026). Company-reported data; peer-reviewed publication status to be confirmed.
[11] Williams Z, et al. Psychedelic therapy vs antidepressants for the treatment of depression under equal unblinding conditions. JAMA Psychiatry. 2026. doi:10.1001/jamapsychiatry.2025.4809
[12] US Food and Drug Administration. Psychedelic Drugs: Considerations for Clinical Investigations – Guidance for Industry. Center for Drug Evaluation and Research; July 2026. https://www.fda.gov/media/169694/download
